Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine

Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibod...

Full description

Bibliographic Details
Main Authors:	Watanabe, Y, Mendonça, L, Allen, ER, Howe, A, Lee, M, Allen, JD, Chawla, H, Pulido, D, Donnellan, F, Davies, H, Ulaszewska, M, Belij-Rammerstorfer, S, Morris, S, Krebs, A-S, Dejnirattisai, W, Mongkolsapaya, J, Supasa, P, Screaton, GR, Green, CM, Lambe, T, Zhang, P, Gilbert, SC, Crispin, M
Format:	Journal article
Language:	English
Published:	American Chemical Society 2021

Similar Items

Native-like SARS-CoV‑2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
by: Yasunori Watanabe, et al.
Published: (2021-04-01)

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
by: Neeltje van Doremalen, et al.
Published: (2022-08-01)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
by: Marchevsky, NG, et al.
Published: (2022)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
by: Natalie Gabrielle Marchevsky, et al.
Published: (2022-07-01)

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial
by: Ewer, K, et al.
Published: (2020)

AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions
by: Md. Altamash Ahmad, et al.
Published: (2023-03-01)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
by: Clemens, SAC, et al.
Published: (2021)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
by: Hillson, K, et al.
Published: (2021)

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients
by: Dharmendra S. Bhadauria, et al.
Published: (2022-10-01)

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination
by: Karina Soboleva, et al.
Published: (2022-01-01)

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
by: Glenn A. Marsh, et al.
Published: (2021-05-01)

Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)
by: Jonathan D. Ho, MBBS, DSc, DipDermpath, et al.
Published: (2022-07-01)

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
by: David Benkeser, et al.
Published: (2023-03-01)

Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine
by: Janaína Jamile Ferreira Saraceno, et al.
Published: (2021-08-01)

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
by: Kaplonek, P, et al.
Published: (2023)

Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
by: Taylor S. Cohen, et al.
Published: (2022-05-01)

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
by: Magdalena E. Sobieszczyk, et al.
Published: (2022-09-01)

REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)
by: Maria da Penha Gomes Gouvea, et al.
Published: (2022-01-01)

SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19)
by: Richard Stebbings, et al.
Published: (2022-04-01)

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
by: Robert J. Fischer, et al.
Published: (2021-10-01)

Immunogenicity after Second ChAdOx1 nCoV-19 (AZD1222) Vaccination According to the Individual Reactogenicity, Health Status and Lifestyle
by: Hyunji Choi, et al.
Published: (2021-12-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
by: Frater, J, et al.
Published: (2021)

Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2
by: Sang Won Lee, et al.
Published: (2021-09-01)

Is a single dose of ChAdOx1 nCoV‐19 vaccine (AZD1222) enough for people with prior SARS‐CoV‐2 infection or baseline seropositive status?
by: Vikas Deswal, et al.
Published: (2022-10-01)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
by: Voysey, M, et al.
Published: (2023)

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
by: Hamaluba, M, et al.
Published: (2023)

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.
by: Swanson, PA, et al.
Published: (2021)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
by: Voysey, M, et al.
Published: (2020)

Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial
by: Michiko Asano, et al.
Published: (2022-01-01)

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
by: Voysey, M, et al.
Published: (2021)

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
by: Piyarat Limpawittayakul, et al.
Published: (2022-11-01)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
by: Emary, KRW, et al.
Published: (2021)

Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population
by: Supamas Sirisreetreerux, et al.
Published: (2023-07-01)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
by: Kriangkrai Tawinprai, et al.
Published: (2023-01-01)

Single-cell RNA sequencing to decipher the immunogenicity of ChAdOx1 nCoV-19/AZD1222 and mRNA-1273 vaccines in patients with autoimmune rheumatic diseases
by: Yen-Ju Chen, et al.
Published: (2022-08-01)

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
by: Spencer, AJ, et al.
Published: (2022)

T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa
by: McMahon, WC, et al.
Published: (2023)

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
by: Lambe, T, et al.
Published: (2021)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
by: Guy Cohen, et al.
Published: (2022-11-01)

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
by: Teresa Lambe, et al.
Published: (2021-07-01)